|Articles|November 24, 2021
GxP regulated industry assessments of SoftMax Pro Software v2
Author(s)Molecular Devices
This document outlines references to 21 CFR Part 11 and EudraLex Annex 11 and how they apply to the implementation of SoftMax Pro GxP Data Acquisition and Analysis Software in regulated environments.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
2
Charles River Incubator Cohort to Accelerate CGT Development
3
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
4
FAQ: Shifts in FDA Regulations and Strategies in 2025
5
